CRSP - The Cards are right for a Massive Explosion to the UpsideCRISPR Therapeutics AGBATS:CRSPimcnf5c4ffRecent Positive News Highlights Positive Phase 1 Clinical Data for CTX310™: CRSP announced impressive results for its CTX310 program targeting ANGPTL3—showing dose-dependent reductions of up to 82% in triglycerides and 81–86% in LDL cholesterol, with a well-tolerated safety profile. These results position CTX310 as a promising treatment for cardiovascular disease. Expanding CASGEVY® Adoption: CASGEVY continues to gain momentum, with more than 65 authorized treatment centers activated globally and over 90 patients enrolled. Sales for CASGEVY, which treats sickle cell disease and transfusion-dependent beta-thalassemia, are described as strong and accelerating. Robust Pipeline and Partnerships: CRSP is advancing multiple next-generation programs in oncology and autoimmune diseases. New collaborations, like the Sirius Therapeutics deal for RNA therapeutics, offer leverage for future innovations and revenue streams. Analyst Upgrade and Stock Surge: CRSP stock has surged 67% since May 2025, prompting Zacks and other analysts to upgrade the rating and predict strong upside potential. The average 12-month forecast is $71.60 (with a high up to $120.00 per share), and the pipeline momentum is shaping an increasingly bullish narrative. Mission and Vision: CRISPR maintains a clear mission—to bring transformative, gene-based medicines to challenging diseases using its proprietary CRISPR/Cas9 technology. Recent financial results reflect large R&D investments with a focus on long-term breakthroughs. I wrote about CRSP many month ago, - this have improved since then more therapies are out. https://www.linkedin.com/pulse/crispr-revolution-comingand-im-betting-big-m-s-sc-n--4zgde/?trackingId=BHXbhQLFRoWzqO9SV%2Fz%2FHg%3D%3D